TORONTO and HAIFA, Israel, April 22, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (NRX:CA) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results